| 产品详情 |
| Edit |   |
|---|
| Product Name | ATB-346 |
|---|
| Description | Purity >98%. ATB-346 is a non-steroidal anti-inflammatory drug (NSAID), derived from naproxen but coupled to an H2 S-releasing moiety. At 30 µmol/kg in rats, it suppressed COX and gastric PGE2 synthesis to the same level as naproxen but reduced COX-2 expression and accelerated recovery in a rat spinal cord injury model. It also provided enhanced anti-inflammatory and antinociceptive activity over naproxen in a rat model of arthritis. ATB-346 does not induce gastrointestinal toxicity and, in contrast to other NSAIDs, it accelerated healing of pre-existing gastric ulcers. Studies of ATB-346 have shown promising results in vitro and in animal models of melanoma and intestinal tumorigenesis. A Phase I clinical trial in Canada did not find any significant gastrointestinal, cardiovascular, renal, or hematological findings across dose ranges in healthy adults (25 mg-2,000 mg once/d). A Phase II trial in Canada is ongoing for patients with osteoarthritis of the knee. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | 6-methoxy-a-methyl-2-naphthaleneacetic acid, 4-(aminothioxomethyl)phenyl ester |
|---|
| Gene, Accession, CAS # | CAS: 1226895-20-0 |
|---|
| Catalog # | LS-H6659 |
|---|
| Price | |
|---|
| Order / More Info | ATB-346 from LIFESPAN BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|